Denali Therapeutics (NASDAQ:DNLI) PT Lowered to $30.00 at Wedbush

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) had its target price dropped by investment analysts at Wedbush from $31.00 to $30.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Wedbush's price target would suggest a potential upside of 58.73% from the company's current price.

A number of other equities analysts have also recently weighed in on DNLI. HC Wainwright reiterated a "buy" rating and set a $95.00 price target on shares of Denali Therapeutics in a report on Wednesday. Stifel Nicolaus dropped their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a "hold" rating for the company in a research report on Wednesday. UBS Group lowered their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, April 9th. Finally, The Goldman Sachs Group cut their target price on Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Denali Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $40.22.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded up $2.05 during trading on Wednesday, hitting $18.90. 2,702,102 shares of the company were exchanged, compared to its average volume of 1,180,243. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.31. The company has a fifty day moving average price of $18.80 and a 200-day moving average price of $18.84. The firm has a market capitalization of $2.69 billion, a PE ratio of -17.50 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter in the prior year, the company posted ($0.80) earnings per share. Research analysts anticipate that Denali Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the business's stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the transaction, the director now owns 118,043 shares in the company, valued at approximately $2,159,006.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Steve E. Krognes sold 92,500 shares of the business's stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the transaction, the director now owns 118,043 shares in the company, valued at $2,159,006.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 110,955 shares of company stock worth $2,218,802. Company insiders own 7.90% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. CWM LLC lifted its position in Denali Therapeutics by 216.7% in the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock valued at $43,000 after acquiring an additional 1,376 shares during the last quarter. Assetmark Inc. boosted its position in shares of Denali Therapeutics by 49.1% in the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company's stock valued at $44,000 after purchasing an additional 707 shares during the period. PNC Financial Services Group Inc. grew its stake in Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company's stock worth $53,000 after buying an additional 807 shares during the last quarter. Fisher Asset Management LLC acquired a new position in Denali Therapeutics during the fourth quarter worth approximately $59,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Denali Therapeutics by 96.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company's stock valued at $73,000 after buying an additional 1,732 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.